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IgSF11 regulates osteoclast differentiation through association
with the scaffold protein PSD-95
Hyunsoo Kim1, Noriko Takegahara1, Matthew C. Walsh1, Sarah A. Middleton2, Jiyeon Yu1, Jumpei Shirakawa1, Jun Ueda3,
Yoshitaka Fujihara3, Masahito Ikawa 3, Masaru Ishii4, Junhyong Kim2 and Yongwon Choi1
Osteoclasts are multinucleated, giant cells derived from myeloid progenitors. While receptor activator of NF-κB ligand (RANKL)
stimulation is the primary driver of osteoclast differentiation, additional signaling further contributes to osteoclast maturation.
Here, we demonstrate that immunoglobulin superfamily member 11 (IgSF11), whose expression increases during osteoclast
differentiation, regulates osteoclast differentiation through interaction with postsynaptic density protein 95 (PSD-95), a scaffold
protein with multiple protein interaction domains. IgSF11 deficiency in vivo results in impaired osteoclast differentiation and
bone resorption but no observed defect in bone formation. Consequently, IgSF11-deficient mice exhibit increased bone mass.
Using in vitro osteoclast culture systems, we show that IgSF11 functions through homophilic interactions. Additionally, we
demonstrate that impaired osteoclast differentiation in IgSF11-deficient cells is rescued by full-length IgSF11 and that the
IgSF11-PSD-95 interaction requires the 75 C-terminal amino acids of IgSF11. Our findings reveal a critical role for IgSF11
during osteoclast differentiation and suggest a role for IgSF11 in a receptor- and signal transduction molecule-containing
protein complex.
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INTRODUCTION
Bone homeostasis is maintained by the balanced functions of
bone-forming osteoblasts and bone-resorbing osteoclasts.1,2
Excessive osteoclast activity can cause pathogenic bone loss,3 so
investigations of the molecular signaling and genetic programs
that control osteoclast differentiation and function are required
both to improve our understanding of osteoclast biology and to
provide a molecular basis for designing therapeutic strategies for
bone remodeling diseases.4
Osteoclasts are specialized multinucleated, giant cells derived
from bone marrow precursors of the monocyte/macrophage
lineage.5,6 Osteoclast differentiation is initiated and sustained
primarily by the osteoclast differentiation factor RANKL,7 which is
mainly produced by osteoblasts and osteocytes.8–10 However,
osteoclast differentiation also requires costimulation by ITAM-
associated surface receptors and cell–cell interactions mediated
by cell adhesion molecules (CAMs).11 CAMs are required not only
to establish cell–cell contacts but also to mediate intracellular
signal transduction for optimal activation and/or differentiation of
the interacting cells.5,12,13
Immunoglobulin superfamily member 11 (IgSF11) was originally
identified as a member of the immunoglobulin superfamily,14 and
it has been revealed to function as a CAM in a calcium-
independent manner.15,16 IgSF11 has been shown to be
predominantly expressed in the brain and testis in mammals.14
In the brain, IgSF11 has been demonstrated to regulate synaptic
transmission and plasticity17 and has also been shown to be
involved in the development of the mouse cerebellum by
suppressing the proliferation and promoting the differentiation
of cerebellar granule cell precursors into cerebellar granule cells.18
In the testis, IgSF11 has been demonstrated to be expressed in
Sertoli cells and to maintain a functional blood–testis barrier.19
Recently, IgSF11 has been identified as a ligand of the B7 family
member V-domain Ig suppressor of T-cell activation (VISTA, also
known as PD-1H),20 which has been revealed to have inhibitory
effects on human T cell function.21 IgSF11 has also been
characterized as a gene frequently upregulated in intestinal type
gastric cancers.22 Although IgSF11 has been revealed to function
as a CAM, IgSF11 has a relatively long cytoplasmic tail (167 amino
acids),23 raising the possibility that it possesses functions beyond
cell adhesion. Indeed, IgSF11 contains a PDZ-binding motif at its
C-terminus and has been demonstrated to interact with intracel-
lular proteins through its PDZ-binding motif, promoting synaptic
transmission and plasticity in neurons.17 This evidence suggests
that the C-terminal cytoplasmic region of IgSF11 has a particular
function.
In the present study, we identified a specific requirement for
IgSF11 that has no previously reported function in the bone, as a
regulator of osteoclast differentiation through interaction with
PSD-95, a scaffold protein with multiple protein interaction
domains. We report here that IgSF11 expression is induced by
RANKL stimulation, and IgSF11 gene deletion results in increased
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bone mass due to impaired osteoclast differentiation but not by
altering osteoblast activities. Using in vitro osteoclast culture
systems, we demonstrate that IgSF11 homophilic interactions are
required for proper osteoclast differentiation. Additionally, we
show that impaired IgSF11-deficient osteoclast differentiation is
restored by full-length IgSF11, which can associate with endo-
genous PSD-95, but is not restored by an IgSF11 mutant in which
the 75 C-terminal amino acids required for association with PSD-
95 have been truncated. RNAi-mediated gene knockdown of PSD-
95 inhibited osteoclast differentiation, suggesting an important
role for PSD-95 in osteoclast differentiation. These results
demonstrate that IgSF11 controls osteoclast differentiation
through association with intracellular molecules via its 75
C-terminal amino acids and suggest a role for IgSF11 not only
as a cell adhesion molecule but also as a mediator of cell signaling
during osteoclast differentiation.
RESULTS
Identification of IgSF11 as an osteoclast differentiation-associated
gene
We previously performed comparative gene expression profiling
to identify novel gene targets associated with the maturation/late
stage of osteoclast differentiation by using multinucleation as a
functional proxy.24 As a result, we identified the gene Igsf11, which
encodes the protein IgSF11, a member of the coxsackievirus and
adenovirus receptor(CAR) subgroup of the CTX (the cortical
thymocyte marker in Xenopus) family of transmembrane
immunoglobulin-like CAMs (Ig-CAMs) (Fig. S1). IgSF11 shares an
identical overall domain organization with a membrane-distal
V-type domain and a membrane-proximal C2-type domain with
coxsackievirus and adenovirus receptor (CAR), endothelial cell-
selective adhesion molecule (ESAM), and CAR-like membrane
protein (CLMP).25–27 To investigate the expression dynamics of
IgSF11 during osteoclast differentiation, we generated osteoclasts
in vitro from mouse bone marrow-derived monocytes (BMMs)
treated with M-CSF+ RANKL for up to three days and performed
temporal Q-PCR-based expression analysis and western blotting.
The expression of IgSF11 gradually increased during culture
and peaked on day two after RANKL treatment at both message
(Fig. 1a) and protein levels (Fig. 1b).
To investigate the role of IgSF11 in osteoclasts, we first
performed RNAi experiments using retrovirus encoding shRNA
specific to IgSF11. BMMs retrovirally transduced with shRNA
against IgSF11 exhibited a reduction in tartrate-resistant acidic
phosphatase-positive (TRAP+) multinucleated cells (i.e., mature
osteoclasts) similar to BMMs transduced with shRNA against
DC-STAMP, a known positive regulator of osteoclast maturation28
(Fig. 1c). We next examined the effect of targeting IgSF11 protein










































































































Fig. 1 Identification of IgSF11 as an osteoclast differentiation-associated gene. a IgSF11 message expression during osteoclast differentiation.
Total RNA was isolated from BMMs cultured with M-CSF+ RANKL for the indicated days and used for Q-PCR. b IgSF11 protein expression
during osteoclast differentiation. Total cell lysates were prepared from BMMs cultured with M-CSF+ RANKL for the indicated days and used
for western blotting with the indicated antibodies. c Effect of IgSF11 RNAi on osteoclast differentiation. BMMs retrovirally transduced with the
indicated shRNAs were cultured with M-CSF+ RANKL for three days. Relative expression of DC-STAMP and IgSF11 was determined by Q-PCR
(left). Cells were stained for TRAP (middle). The frequency of TRAP+ multinucleated cells is shown (right). The scale bar represents 100 μm.
d Effect of antibodies on osteoclast differentiation. BMMs were cultured with M-CSF+ RANKL for three days in the presence of the indicated
antibodies (left). The frequency of TRAP+ multinucleated cells (3 nuclei or more per cell) is shown (right). The scale bar represents 100 μm.
Data are shown as the mean ± S.D. ***P < 0.001
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antibody. Control IgG and anti-DC-STAMP antibodies were used as
negative and positive controls, respectively. The addition of either
anti-IgSF11 or anti-DC-STAMP caused a significant reduction in
TRAP+ multinucleated cells (Fig. 1d). These results suggest a
potential regulatory role for IgSF11 in osteoclast maturation.
IgSF11 regulates osteoclast differentiation and bone metabolism
To better understand the role of IgSF11 in osteoclasts and its
function in bone remodeling, we generated IgSF11-deficient
(IgSF11−/−) mice using clustered regularly interspersed short
palindromic repeats (CRISPR)/Cas9 technology (Fig. S2a). We
obtained gene knockout mice carrying a deletion of 48 base pairs
(bp) (via a 55 bp deletion and 7 bp insertion event) in exon 1 of
Igsf11 (Fig. S2b). Mouse genotypes were verified by PCR (Fig. S2c),
and the gene deletion was confirmed by western blotting (Fig.
S2d). Similar to previous reports, male IgSF11−/− mice were found
to exhibit smaller testis and infertility,19 albeit with no apparent
differences in body weight or size observed between IgSF11+/+
and IgSF11−/− mice (Fig. S2e and data not shown). No generative
dysfunction was observed in IgSF11+/− males or IgSF11−/−
females19 (data not shown).
To determine the specific cell-intrinsic role of IgSF11, we
isolated BMMs from IgSF11+/+ and IgSF11−/− mice and cultured
them with M-CSF+ RANKL to generate osteoclasts. We found
significant reductions in total TRAP activity and in the frequency of
multinucleated TRAP+ cells in IgSF11−/− cultures compared to
IgSF11+/+ cultures (Fig. 2a). No significant difference in osteoclast
survival was observed (Fig. S3). Message levels of markers of
differentiated osteoclasts, Acp5 and Ctsk, were also reduced in
IgSF11−/− cultures (Fig. 2b). However, signaling pathways involved
in early differentiation, such as expression/activation of important
transcription factors (c-fos, NFATc1, and NF-κB) and activation of
ITAM signaling (Syk, and PLCγ2), seemed to be comparable
between IgSF11+/+ and IgSF11−/− cells (Fig. 2b and Fig. S4).
Similar to the reduction in osteoclast markers, we found significant
reductions in overall resorption areas and in pit area per osteoclast
in IgSF11−/− cultures (Fig. 2c). Retroviral transduction of IgSF11−/−
BMMs with full-length IgSF11 completely rescued the impaired
TRAP+ multinucleated cell formation, and furthermore, transduc-
tion of IgSF11+/+ BMMs with IgSF11 significantly enhanced TRAP+
multinucleated cell formation (Fig. 2d). These results suggest that
IgSF11 positively regulates osteoclast differentiation and that the
phenotypes observed in IgSF11−/− osteoclast cultures can be
attributed to deletion of the Igsf11 gene.
We next examined whether IgSF11 deficiency affects bone
development and homeostasis. By immunohistochemistry of bone
sections of mice in which osteoclasts and osteoblasts were labeled
with red and cyan fluorescent proteins, respectively (TRAP-
tdTomato/Col2.3-ECFP),29 we found IgSF11 protein expression in
red+ (osteoclast) cells (Fig. S5a). In contrast, IgSF11 was barely
detected in cyan+ (osteoblast) cells (Fig. S5a) or in bone matrix-
embedded cells (osteocytes, data not shown). These results
suggested that IgSF11 is expressed in osteoclasts among bone
cells in vivo. We confirmed no detection of IgSF11 in bone
sections of IgSF11−/− mice (Fig. S5b). We then prepared gender-
and age-matched IgSF11+/+ and IgSF11−/− mice and performed
representative 3D reconstructions of trabecular bone. Bone
microstructure imaging by high-resolution microcomputed tomo-
graphy (μCT) of IgSF11−/− male mice revealed significantly
increased bone mass, characterized by increased bone indices
that included trabecular bone volume per tissue volume (BV/TV),
trabecular number (Tb.N), trabecular thickness (Tb.Th), and bone
mineral density (BMD), with concomitant decreases in trabecular
spacing (Tb.Sp) (Fig. 3a). No significant differences in cortical bone
thickness (Ct.Th) were detected between IgSF11+/+ and IgSF11−/−
mice (Fig. 3a). A similar tendency toward increased bone mass was
also observed in IgSF11−/− female mice (Fig. S6). TRAP-stained
IgSF11−/− bone sections revealed a significant reduction in the
number of osteoclasts on the bone surface (N.Oc/BS) compared to
the number in IgSF11+/+ sections (Fig. 3b). In contrast, quantita-
tion of the osteoblast number per bone surface (N.Ob/BS)
revealed normal numbers of osteoblasts in bone sections from
IgSF11−/− mice (Fig. 3b). Serum levels of the bone resorption
markers C-terminal telopeptide of type I collagen (CTX-I) and
tartrate-resistant acid phosphatase 5b (TRACP-5b) were both
found to be reduced in IgSF11−/− mice (Fig. S7). In contrast, serum
levels of osteocalcin, a bone formation marker, showed no
significant differences between IgSF11+/+ and IgSF11−/− mice
(Fig. S7). Dynamic histomorphometry by sequential injections of
calcein and xylenol orange revealed normal bone formation rates
in IgSF11−/− mice (Fig. 3c). In addition, in vitro osteogenic
differentiation exhibited no differences in IgSF11−/− calvaria-
derived osteoblast precursors compared to those from IgSF11+/+
calvaria as visualized by alizarin red staining for mineralized
nodule formation and calcium deposits (Fig. 3d). These results
suggest that IgSF11 deficiency results in increased bone mass due
to impaired osteoclast differentiation but not impaired osteoblast
development or function.
IgSF11 functions through homophilic interactions
Having shown that IgSF11 regulates bone metabolism through
regulation of osteoclast differentiation, we sought to identify the
molecular mechanism that regulates IgSF11-mediated osteoclast
differentiation. IgSF11 has been reported to mediate cell–cell
adhesion as a CAM.15 We found that RANKL-treated BMMs
expressing EGFP-tagged IgSF11 showed accumulation of EGFP at
cell–cell contacts (Fig. S8a), suggesting the involvement of IgSF11
in intercellular interactions during osteoclast differentiation.
IgSF11 has been reported to engage in both homophilic
interactions15 and in heterophilic interactions with VISTA.20,21 By
flow cytometric analysis, we found VISTA expression on both
IgSF11+/+ and IgSF11−/− BMMs (Fig. S8b), raising the potential
for involvement of VISTA in osteoclast differentiation through an
interaction with IgSF11. To determine the type of of interaction
involved in osteoclast differentiation, we generated a recombi-
nant soluble IgSF11-Fc protein that consisted of the extracellular
region of IgSF11 fused to the human IgG Fc region. We performed
binding assays using IgSF11-Fc, which revealed dose-dependent
binding of IgSF11-Fc to IgSF11-expressing 293 T cells but not to
VISTA-expressing 293 T cells (Fig. 4a). We also found that
treatment with IgSF11-Fc significantly reduced RANKL-induced
formation of TRAP+ multinucleated cells in IgSF11+/+ cultures in
a dose-dependent manner, whereas no inhibitory effect of
IgSF11-Fc was observed in IgSF11−/− cultures (Fig. 4b). In
contrast, when we examined the effect of recombinant soluble
VISTA-Fc protein on the formation of TRAP+ multinucleated cells,
no apparent effect was observed in IgSF11+/+ or IgSF11−/−
cultures (Fig. 4b). These results show that IgSF11-Fc perturbs
osteoclast differentiation and suggest that IgSF11-mediated
osteoclast differentiation depends on an IgSF11-IgSF11 homo-
philic interaction.
The PSD-95-associated region of IgSF11 is required for osteoclast
differentiation
We sought to further investigate the mechanism by which IgSF11
regulates osteoclast differentiation. To gain insight into IgSF11
function, we generated mutant expression vectors lacking various
sections of the IgSF11 intracellular region (IgSF11-Mt275 lacks the
entire intracellular region, IgSF11-Mt323 lacks 105 amino acids
from the C-terminus, and IgSF11-Mt353 lacks 75 amino acids from
the C-terminus) (Fig. 5a). IgSF11−/− BMMs were retrovirally
transduced with full-length IgSF11 (IgSF11-FL) or mutant vectors
and cultured with M-CSF+ RANKL to generate osteoclasts.
Compared to the full recovery of TRAP+ multinucleated cell
numbers by IgSF11-FL, IgSF11-Mt275 failed to rescue the formation
of TRAP+ multinucleated cells (Fig. 5b), suggesting a critical role
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for the IgSF11 intracellular region during osteoclast differentiation.
Both IgSF11-Mt323 and IgSF11-Mt353 mutants also failed to restore
TRAP+ multinucleated cells (Fig. 5b), suggesting a specific
requirement for the 75 C-terminal amino acids of IgSF11 for
osteoclast differentiation.
It has been reported that IgSF11 interacts with PSD-9517
through the IgSF11 C-terminal PDZ-binding motif (PB). PSD-95
is a specialized scaffold protein with multiple protein interac-
tion domains and forms the backbone of an extensive
postsynaptic protein complex that organizes receptors and
signal transduction molecules at the synaptic contact zone.30
To investigate the involvement of PSD-95 in osteoclast
differentiation, we tested whether IgSF11 forms a signaling
complex with PSD-95 in osteoclasts. For this, we retrovirally
transduced flag-tagged full-length IgSF11 or the C-terminal
deletion mutant form of IgSF11 into IgSF11-deficient cells and
performed coimmunoprecipitation to examine whether IgSF11
associates with PSD-95. We found, as predicted, that IgSF11-FL
associates with PSD-95 (Fig. 5c). In contrast, an association of
IgSF11-Mt353 with PSD-95 was not observed. Furthermore, we
performed RNAi-mediated gene knockdown of PSD-95 in
osteoclasts. Wild-type BMMs retrovirally transduced with shRNA
against PSD-95 exhibited significant reductions in the
frequency of multinucleated TRAP+ cells (Fig. 5d). These results
suggest that PSD-95 plays a role in osteoclasts and that the
association of IgSF11 with PSD-95 through the 75 amino acids
at the IgSF11 C-terminus is specifically required for proper
osteoclast differentiation.
DISCUSSION
During osteoclast differentiation, RANKL stimulation drives the
commitment of osteoclast precursors to become large multi-
nucleated mature osteoclasts. In addition to RANKL stimulation,
costimulation and cell–cell interactions through surface receptors
are further required to provide additional signaling necessary for
osteoclast maturation. In this study, we revealed that IgSF11, a
member of the Ig-CAM family, engages in homophilic interactions
and leads to increased osteoclast differentiation through associa-
tion with PSD-95. Our findings reveal a critical role for IgSF11 in
osteoclast differentiation.
We showed that IgSF11 is involved in osteoclast differentiation
and maturation. Although we cannot rule out a role for IgSF11
during the early stage of differentiation characterized by TRAP+
mononuclear preosteoclasts, most of the early stage signaling




















































































































































































































Fig. 2 IgSF11 regulates in vitro osteoclast differentiation. a Osteoclast differentiation of IgSF11+/+ and IgSF11−/− cells. BMMs were cultured
with M-CSF+ RANKL for the indicated days (top). TRAP activity and frequency of TRAP+ multinucleated cells (3 nuclei or more per cell) are
shown (bottom). The scale bar represents 100 μm. b Gene expression during osteoclast differentiation. Total RNA was collected from
IgSF11+/+ and IgSF11−/− cultured cells, and the levels of the indicated genes were measured by Q-PCR. c Bone resorption activity of
IgSF11+/+ and IgSF11−/− osteoclasts. IgSF11+/+ and IgSF11−/− BMMs were cultured with M-CSF+ RANKL for three days, harvested, and
recultured on dentin slices. The resorption area and pit are shown per cell. The scale bar represents 100 μm. d Osteoclast differentiation
rescued by retroviral transduction of IgSF11 in IgSF11−/− BMMs. BMMs were retrovirally transduced with empty vector (EV) or Flag-tagged
IgSF11 expression vector followed by culture with M-CSF+ RANKL for three days. The frequency of TRAP+ multinucleated cells (3 nuclei or
more per cell) is shown. Expression of exogenous IgSF11 was confirmed by western blotting with an anti-Flag antibody. The scale bar
represents 100 μm. Data are shown as the mean ± S.D. ***P < 0.001
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unaffected. In contrast, the difference between IgSF11+/+ and
IgSF11−/− cultures was more obvious when we counted TRAP+
large multinucleated osteoclasts. Hence, IgSF11 deficiency is likely
to have a more significant effect on the process of osteoclast
maturation required for the formation of multinucleated
giant cells.
We sought to identify the molecular mechanisms by which
IgSF11 regulates osteoclast differentiation by generating mutant
expression vectors lacking various sections of the IgSF11
intracellular region and identified that the region encompassing
the 75 C-terminal amino acids of IgSF11 is important for osteoclast
differentiation. We also revealed that PSD-95 is involved in
osteoclast differentiation and that IgSF11 associates with PSD-95
through the C-terminal 75 amino acid region and forms a protein
complex in osteoclasts. Given that PSD-95 forms the backbone of
a protein complex in the nervous system,31 it is plausible that the
IgSF11-PSD-95 protein complex plays a role in the regulation of
signal transduction at the cell–cell contact site during osteoclast
differentiation. Indeed, PSD-95 is known to interact with a large
number of proteins, including Src family kinases, through its three
PDZ domains, SH3 domain, and/or guanylate kinase domain and
can also multimerize to form an extended scaffold.32,33 It is also
possible that the IgSF11 C-terminal region recruits additional
proteins and/or signaling molecules. Further study is needed to
clarify the mechanism underlying IgSF11-mediated regulation of
osteoclast differentiation.
IgSF11 has been shown to engage in homophilic interactions as





































































































































































































Fig. 3 IgSF11 deficiency results in increased bone mass in mice. a Microcomputed tomography (μCT) images of femurs from IgSF11+/+ and
IgSF11−/− mice. The femurs of 12-week-old male mice were analyzed. Bone volume per tissue volume (BV/TV), trabecular thickness (Tb.Th),
trabecular number (Tb.N), trabecular spacing (Tb.Sp), bone mineral density (BMD), and cortical thickness (Ct.Th) are shown. Scale bars
represent 0.5 mm. b Histological analysis of tibias from 12-week-old IgSF11+/+ and IgSF11−/− mice. Tibial sections were stained with TRAP or
H&E. Osteoclast number per bone surface (N.Oc/BS) and osteoblast number per bone surface (N.Ob/BS) are shown. Scale bars represent
100 μm. c Dynamic histomorphometry of tibias from 12-week-old IgSF11+/+ and IgSF11−/− mice. Mineral apposition rate (MAR) and
bone formation (BFR) are shown. The scale bar represents 50 μm. d IgSF11+/+ and IgSF11−/− bone marrow-derived stromal cells (BMSCs)
were cultured with osteogenic medium for the indicated days and then stained with alizarin red. Data are shown as the mean ± S.D. *P < 0.05,
**P < 0.01, ***P < 0.001
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involved in T cell activation.34,35 Although we observed expression
of VISTA on BMMs and preosteoclasts (Fig. S8b), we cannot
conclude that IgSF11-VISTA interactions are operative in osteoclast
differentiation given that (1) we found neither inhibitory nor
stimulatory effects of functional VISTA-Fc on osteoclast differ-
entiation, (2) IgSF11-Fc inhibited IgSF11+/+ osteoclast differentia-
tion to the same degree as that of IgSF11−/− osteoclasts, and (3)
IgSF11-Fc showed no inhibitory effects on IgSF11−/− culture. We
did not find heterophilic interactions between IgSF11 and VISTA.
The discrepancy between previous studies and this study may be
explained by differences in experimental systems, different
recombinant IgSF11 proteins, and a different binding assay
system. Nevertheless, the recombinant IgSF11-Fc used in this
study was functionally active with respect to its effects on
osteoclast differentiation (Fig. 4b). These results suggest that
IgSF11 regulates osteoclast differentiation through homophilic
interactions.
Here, we demonstrated that intracellular region-truncated
mutants (IgSF11-Mt257, IgSF11-Mt323, and IgSF11-Mt353; in all the
extracellular region was intact) failed to rescue the impaired
osteoclast differentiation in IgSF11−/− cultures. These results imply
that although the cell–cell adhesion function mediated by IgSF11
through homotypic interactions may be important in some
contexts, it does not appear to be essential for osteoclast
differentiation. Rather, signaling mediated through the IgSF11
intracellular region by IgSF11 homotypic interactions is more likely
required for osteoclast differentiation. IgSF11 might function not
just as a CAM but as a mediator of signaling necessary for
osteoclast differentiation.
Bone remodeling is carried out by tightly controlled coupling of
osteoclastic bone destruction and osteoblastic bone formation.1,36
This coupling is key to preserving bone architecture and strength.
Current treatments for bone loss, such as bisphosphonates and
anti-RANKL antibody (Denosumab), primarily target early osteo-
clast commitment and/or osteoclast viability.37 However, these
treatments often fail to uncouple bone degradation and formation
and result in compromised bone strength due to unintended
inhibition of coupled bone formation.38,39 We focused on IgSF11
in a study aiming to identify gene targets associated with the
maturation/late stage of osteoclast, which we believe will identify
better treatment targets (inhibit osteoclast resorption without
preventing contribution to production bone formation),24 and we
showed that IgSF11 deficiency uncoupled bone degradation and
formation and impaired osteoclast-mediated bone resorption
without affecting osteoblast-mediated bone formation. These
results suggest that IgSF11 might be a promising target for
selectively inhibiting bone loss.
In conclusion, we identified a previously unknown function of
IgSF11 as a regulator of osteoclast differentiation. Identification
and characterization of additional key regulators of osteoclast
differentiation would aid in the development of therapeutic
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Fig. 4 IgSF11 functions through homophilic interactions. a Staining of IgSF11- or VISTA-expressing 293 T cells with IgSF11-Fc protein.
293 T cells were transiently transfected with N-terminal Flag-tagged IgSF11 or VISTA expression vector and incubated with the indicated
concentration of IgSF11-Fc, followed by staining with anti-human IgG-PE antibody. Control human IgG was used as a negative control. Surface
expression of IgSF11 and VISTA was confirmed by staining with anti-Flag or anti-VISTA antibodies, respectively. b Effects of recombinant
IgSF11 or VISTA proteins on osteoclast differentiation. IgSF11+/+ and IgSF11−/− BMMs were cultured with M-CSF+ RANKL plus the indicated
concentration of recombinant protein for three days. The frequency of TRAP+ multinucleated cells (3 nuclei or more per cell) is shown. Scale
bars represent 100 μm
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IgSF11−/− mice were generated using CRISPR/Cas9 technology
with the cooperation of NPO Biotechnology Research and
Development.40 A small guide RNA (sgRNA) targeting IgSF11
exon 1 was synthesized in vitro. C57BL/6 female mice were
superovulated, and oocytes were collected from the ampullae and
then coincubated with sperm from C57BL/6 male mice. Pronuclear
stage eggs were injected with pX330 plasmids containing
hCas9 and sgRNA (5′- GGCGGCGCTCCGCTCCGGCGTCCTGG-3′) at
5 ng·mL−1 using a micromanipulator. The fertilized eggs were
transferred into the oviducts of pseudopregnant ICR females, and
F0 generation mice were born. F0 offspring were genotyped using
PCR amplification and subsequent direct sequencing. Five of the
seven offspring carried a nonmosaic genomic mutation. We bred
one of these mice carrying a heterozygous 48 bp deletion
mutation with the C57BL/6 background strain. Homozygous
mutant mice were bred from F1 heterozygotes. All neonatal mice
were genotyped by sanger sequencing using the following
primers: 5′- GTTCTGTGCATTCTGCGGCT-3′ (sense) and 5′-TATCG
CAAACTCCTTCAAGGCT-3′ (antisense), which generated products
of 625 bp for the wild-type allele and 577 bp for the mutant allele,
and/or polymerase chain reaction (PCR) using the following
primers: 5′-GCTTGGTCCCACGCTGCACC-3′ (sense) and 5′-CTCACC-
GAGCAGCGACACGA-3′ (antisense), which generated product of
125 bp for the wild-type allele and 77 bp for the mutant allele. In
each experiment, homozygous IgSF11+/+ and IgSF11−/− litter-
mate mice that were generated by intercrossing heterozygous
mice were compared. All mice were maintained and used in
accordance with guidelines approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of
Pennsylvania.
Reverse transcription and real-time PCR (Q-PCR)
Total RNA was extracted from cells using TRIzol reagent (Invitro-
gen), and 1μg–5 μg of total RNA was reverse transcribed using
random hexamer primers and SuperScript III reverse transcriptase
(Invitrogen). cDNA corresponding to 10 ng of total RNA was
analyzed by Q-PCR using a QuantStudio3 (Applied Biosystems) and
the following specific TaqMan® probes: IgSF11 (Mm00464360_m1),
ACP5 (Mm00475698_m1), DC-STAMP (Mm01168058_m1), Ctsk
(Mm00484036_m1), PSD-95 (Mm00492193_m1), and 18 S
(Hs99999901_s1). The CT method of relative quantification was
























































































































































Fig. 5 IgSF11-PSD-95 protein complex formation is required for IgSF11-mediated regulation of osteoclast differentiation. a Schema of IgSF11
wild type and IgSF11 deletion mutants to be used for retroviral transduction of IgSF11−/− BMMs. All constructs were Flag-tagged at the C-
terminus (left). IgSF11+/+ BMMs were used as controls. Protein expression was confirmed by western blotting with an anti-Flag antibody
(right). PB, PDZ-binding domain. b The cells prepared in a were cultured with M-CSF+ RANKL and stained for TRAP. The frequency of TRAP+
multinucleated cells (3 nuclei or more per cell) is shown. Scale bars represent 100 μm. c Coimmunoprecipitation of IgSF11 with PSD-95.
IgSF11−/− BMMs retrovirally transduced with the indicated vectors were lysed and immunoprecipitated with anti-Flag antibody, and western
blotting was performed with the indicated antibodies. d Effect of PSD-95 RNAi on osteoclast differentiation. BMMs retrovirally transduced with
the indicated shRNAs were cultured with M-CSF+ RANKL for three days. The relative expression of PSD-95 was determined by Q-PCR.
Cells were stained for TRAP. The frequency of TRAP+ multinucleated cells is shown. The scale bar represents 100 μm. Data are shown as the
mean ± S.D.
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Western blotting
BMMs and osteoclast cultures were washed with ice-cold
phosphate-buffered saline (PBS) and lysed with ice-cold radio
immunoprecipitation (RIPA) lysis buffer (20 mmol·L−1 Tris-HCl, pH
7.5, 150 mmol·L−1 NaCl, 1% NP-40, 0.5% sodium deoxycholate,
1 mmol·L−1 EDTA, 0.1% SDS, protease and phosphatase inhibitor
cocktail (Roche)). The lysates were centrifuged to remove debris,
and protein concentrations were determined using the Bradford
assay. Equal amounts of lysates (2 μg–50 μg of protein) were
fractionated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) on 4%–12% gradient gels and transferred onto
polyvinyl difluoride (PVDF) membranes. Western blotting was
performed with the following antibodies: anti-IgSF11 (2067 and
2068), which was a kind gift from Dr. Eunjoon Kim (KAIST, Korea),
anti-p-IkBα: 2859, anti-Syk: 2712, anti-p-Syk: 2701, anti-PLCγ2:
3872, and anti-p-PLCγ2: 3874 (Cell Signaling Technology), anti-
Flag: M2 (Sigma-Aldrich), anti-actin: sc-47778 (Santa Cruz Biotech-
nology), and anti-PSD-95: K28/43 (BioLegend).
Microcomputed tomography
Femurs from 12-week-old IgSF11+/+ and IgSF11−/− male mice
and 16-week-old female mice were harvested, fixed for 1 h in 4%
formalin, and then incubated with PBS. Scanning was performed
using μCT (μCT35, SCANCO Medical AG, Brüttisellen, Switzerland).
For trabecular bone analysis, scans were performed at the distal
femoral metaphysis 0.4 mm proximal to the growth plate. For
cortical bone, mid-diaphysis of femurs was scanned. All scans
were performed at a resolution of 6 μm per slice using an X-ray
energy of 55 kvp and an integration time of 300 ms. A total of
200 slices for trabecular bone and 50 slices for cortical bone were
analyzed using the instrument’s software.
Bone histology and histomorphometry
For histology and histomorphometry, 12-week-old IgSF11+/+
and IgSF11−/− mice were perfused with 4% paraformaldehyde
plus sucrose for fixation, and bone tissues were further fixed
with 4% paraformaldehyde plus sucrose for 3 h at 4 °C. Bones
were incubated with 10% EDTA for 2 weeks for decalcification
and embedded in O.C.T. compound (Tissue-Tek). Longitudinal
sections, 10 μm thick, were prepared using Kawamoto’s film
method41 and stained with H&E for OB parameter analysis or
stained with TRAP for OC parameter analysis within the primary
and secondary spongiosa. Measurement of mineral apposition
rate was performed as described previously.42 In brief, 12-week-
old IgSF11+/+ and IgSF11−/− mice were injected with calcein,
then with xylenol orange 10 days later, and then killed 2 days
after that. For immunohistochemistry, bone samples of 9-week-
old IgSF11+/+/TRAP-tdTomato/Col2.3-ECFP mice, which were
prepared by perfusion with 4% paraformaldehyde plus sucrose
and further fixed with 4% paraformaldehyde plus sucrose for
16 h at 4 °C, were obtained and embedded in SCEM (SECTION-
LAB). Longitudinal sections, 10 μm thick, were prepared using
Kawamoto’s film method. Fluorescence and phase-contrast
images were acquired using a laser-scanning confocal micro-
scope (TCS SP8, Leica) and analyzed using NIS Elements
software (NIKON). The following antibodies were used for
blocking: goat F(ab) anti-mouse IgG H&L: ab6668 (Abcam) and
anti-CD16/CD32 monoclonal antibody (93): 14-0161 (Thermo
Fisher Scientific). The following antibodies and dye were used
for staining: anti-IgSF11: sc-393816 (Santa Cruz Biotechnology),
Alexa Fluor 488 goat anti-mouse IgG (H+ L): A11029 (Thermo
Fisher Scientific), and TO-PRO-3 iodide: T3605 (Thermo Fisher
Scientific).
In vitro osteoclast (OC) differentiation and tartrate-resistant acid
phosphatase (TRAP) staining
BMMs and osteoclasts were prepared, as described previously.43 In
brief, whole BM was extracted from the femurs and tibias of mice
and incubated in 100 mm petri dishes in α-MEM containing 10%
fetal bovine serum and M-CSF (5 ng·mL−1) overnight. Non-
adherent cells were collected and cultured for 3 days with
M-CSF (30 ng·mL−1) to generate BMMs. For OC differentiation,
BMMs were plated at 5 × 103 per well in 96-well cell culture
plates and cultured with M-CSF (60 ng·mL−1) and RANKL
(150 ng·mL−1) for 3 days. Osteoclasts were stained using the
Acid, Phosphatase, Leukocyte (tartrate-resistant acid phospha-
tase) Kit (387A-1KT, Sigma) following the manufacturer’s
instructions. To analyze bone pit formation, BMMs were cultured
with M-CSF and RANKL for 3 days to differentiate into
osteoclasts. Differentiated osteoclasts were harvested and
seeded on dentin slices at 2 × 104 per well in 96-well cell culture
plates and cultured for 3 additional days. Cells on dentin slices
were removed by washing with PBS and stained with 1%
hematoxylin. Resorption pits were visualized under a light
microscope. Pit area was measured by ImageJ (National
Institutes of Health). Anti-DC-STAMP (MABF39) and anti-IgSF11
(sc-393816) antibodies were purchased from EMD Millipore,
Santa Cruz Biotechnology, and BioLegend, respectively. Recom-
binant human IgSF11-Fc chimera protein was produced by
Accurus Biosciences. To do so, cDNA from the reported clone
GenBank AY358141 was modified to improve protein expression
stability by deleting the two C-terminal amino acids and then
subcloned in-frame with an N-terminal proprietary (Accurus)
signal peptide, a C-terminal ECD linker, and the sequence for the
human IgG1 Fc region. This construct was then stably transfected
into CHO cells, and the secreted protein was purified. Recombi-
nant mouse VISTA-Fc chimera protein (7005-B7) was purchased
from R&D.
In vitro osteogenic differentiation
The osteoblast differentiation assay was performed, as previously
described.44 In brief, bone marrow stromal cells were seeded at
1 × 105 cells/well in 48-well plates with osteogenic medium
containing 10% FBS, 10 mmol·L−1 β-glycerophosphate, and
ascorbic acid (100 μg·mL−1) for 24 days. Mineralized nodule
formation was determined on days 8, 16, and 24 by staining with
alizarin red S solution (ARS). ARS stock solution was prepared by
dissolving 1 mg of alizarin red S in 100 mL of 1% KOH. At the
designated time point (depending on the experiment) of a given
culture in osteogenic induction medium, cells were washed,
fixed, and then stained with 40 mmol·L−1 fresh ARS solution
(pH 4.2). Calcium deposits were then visualized by red color
under light microscopy. To quantify the staining, the ARS
Staining Quantification Assay (ARed-Q) method (ScienCell
Research Laboratories, Carlsbad, CA, USA) was used based on
the manufacturer’s instructions. The desired ARS dye was
quantified by measuring the absorbance at 405 nm.
Flow cytometric analysis
In total 293 T cells transfected with expression vectors encoding
IgSF11 (Flag-tagged at the N-terminus) or VISTA (Flag-tagged at
the C-terminus) were washed with PBS and detached using
enzyme-free cell dissociation buffer (Millipore). After preparing
single-cell suspensions, cells were incubated with the indicated
concentration of IgSF11-Fc or control human IgG for 30 min on ice.
After washing, the cells were stained with PE-labeled goat anti-
human IgG for 15 min on ice. After washing again, cells were
stained with TO-PRO-3 (Life Technology, Inc.) to exclude dead cells
and analyzed using an LSR (BD Bioscience) analyzer. Surface
expression of IgSF11 and VISTA was confirmed using anti-Flag and
anti-VISTA antibodies, respectively.
Retrovirus preparation and transduction
Mouse IgSF11 cDNA was amplified by PCR with the following
primers: a sense primer with the EcoRI site (5′-GGGAATT
CAGTGGCCTCGGCGCTCCCGTGTCC-3′) and antisense primers with
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the XhoI site (5′-CTCGAGTACCAGGGACCCTGCTCGACTCTG-3′ for
IgSF11-FL, 5′-AACTCGAGTGATGGGATAACTGCATT-3′ for IgSF11-
Mt353, 5′-CTCGAGGTTGTTCCA GTATCGACTGTTGTA-3′ for IgSF11-
Mt323, and 5′-CTCGAGCTCCTCCTCTTTGTTTTTGCTTCT-3′ for IgSF11-
Mt275) and cloned into the EcoRI-XhoI fragment of the pMX-Flag
vector to generate pMX vectors encoding C-terminally FLAG-
tagged IgSF11-FL, IgSF11-Mt353, IgSF11-Mt323, and IgSF11-Mt275.
To prepare retroviral particles, Plat-E packaging cells were plated
on 100mm culture dishes and cotransfected with pSuper vectors
encoding siRNAs targeting IgSF11 (5′-AGTAATAGCCGGAGCGGTT-
3′), DC-STAMP (5′-GAATGACACTAGAGGAGAA-3′), and PSD-95 (sh-
1: 5′-GGAACAGCTTATGAATAGT-3′, and sh-2: 5′-GTTCACG-
GAGTGCTTCTCA-3′), and pMX vectors encoding C-terminally
FLAG-tagged IgSF11-FL, IgSF11-Mt353, IgSF11-Mt323, and IgSF11-
Mt275 using PEImax (Polysciences). Empty pSuper vector and pMX
vector were used as negative controls. After 3 days, medium
containing each retrovirus was harvested and passed through a
syringe filter (0.45 μm pore diameter). BMMs were transduced with
retroviruses for 16 h with hexadimethrine bromide (8 μg·mL−1) in
the presence of M-CSF (60 ng·mL−1). After washing with fresh
medium, infected cells were selected by culturing for 2 days in the
presence of puromycin (2 μg·mL−1) and M-CSF (60 ng·mL−1).
Puromycin-resistant BMMs were used for the experiments.
Statistical analysis
All experiments were analyzed using one-way ANOVA or 2-tailed
paired Student’s t test with Prism 7.0 (GraphPad Software). P < 0.05
was considered statistically significant.
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